cd34 a700 Search Results


cd34-a700 antibody  (Thermo Fisher)
90
Thermo Fisher cd34-a700 antibody
Cd34 A700 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd34-a700 antibody/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
cd34-a700 antibody - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
anti cd34 a700  (Thermo Fisher)
86
Thermo Fisher anti cd34 a700
Anti Cd34 A700, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd34 a700/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
anti cd34 a700 - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier
cd34 a700  (R&D Systems)
93
R&D Systems cd34 a700
ITPP reduces melanoma tumor growth and improves mice survival. a Effect of ITPP treatment on the kinetics of tumor growth measured by bioluminescence in treated and nontreated animals at days 18 and 24. Endpoint was fixed at 2 cm 3 ( n = 6 animals per group, one representative experiment out of N > 10, ** p < 0.001). b Comparison of tumor size, 23 days after B16F10LucGFP cells injection, showing reduced tumor growth in treated mice. Representative groups of five animals among groups of n = 10 animals. One experiment out of N ≥ 5 separate experiments. Insets illustrate the extreme size ranges (minimal and maximal) that tumor reached in nontreated compared to treated mice. c Mean size of the tumors in treated and non treated animals at day 23 ( n = 10 in each group; number of experiments N > 20, ** p < 0.001). d Magnetic resonance imaging of B16 F10 induced tumor. Morphological pulse sequence ( left ). Strong volume variation of the tumor (untreated/ITPP = 1163 mm 3 /121 mm 3 ) was observed by image analysis after volume reconstruction. One typical example out of n = 10/experimental group. MRA-TOF/saturation recovery pulse sequence ( right ): Necrotic areas appear darker. After ITPP treatment, their size decreased. One typical example out of n = 10/experimental group. e Analysis by flow cytometry of B16LucGFP cells in tumors. Luciferase was detected intracellularly by specific antibodies and labeled by PerCP-Cy7 antirabbit <t>IgG</t> confirming: the reduced growth of tumor cells in ITPP-treated mice (%) and counts by direct cytometry analysis. Cells were numbered on the basis of intracellular Luciferase detection ( n = 8; * p < 0.05) from dot plots or inset from histogram analysis for quantification of B16F10LucGFP in the tumor
Cd34 A700, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd34 a700/product/R&D Systems
Average 93 stars, based on 1 article reviews
cd34 a700 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
alexa fluor 700 anti human cd34  (BioLegend)
N/A
Alexa Fluor 700 anti human CD34 581 Isotype Mouse IgG1 κ Reactivity Human Cross Reactivity Cynomolgus Apps FC IF Size 25 tests
   Buy from Supplier

Image Search Results


ITPP reduces melanoma tumor growth and improves mice survival. a Effect of ITPP treatment on the kinetics of tumor growth measured by bioluminescence in treated and nontreated animals at days 18 and 24. Endpoint was fixed at 2 cm 3 ( n = 6 animals per group, one representative experiment out of N > 10, ** p < 0.001). b Comparison of tumor size, 23 days after B16F10LucGFP cells injection, showing reduced tumor growth in treated mice. Representative groups of five animals among groups of n = 10 animals. One experiment out of N ≥ 5 separate experiments. Insets illustrate the extreme size ranges (minimal and maximal) that tumor reached in nontreated compared to treated mice. c Mean size of the tumors in treated and non treated animals at day 23 ( n = 10 in each group; number of experiments N > 20, ** p < 0.001). d Magnetic resonance imaging of B16 F10 induced tumor. Morphological pulse sequence ( left ). Strong volume variation of the tumor (untreated/ITPP = 1163 mm 3 /121 mm 3 ) was observed by image analysis after volume reconstruction. One typical example out of n = 10/experimental group. MRA-TOF/saturation recovery pulse sequence ( right ): Necrotic areas appear darker. After ITPP treatment, their size decreased. One typical example out of n = 10/experimental group. e Analysis by flow cytometry of B16LucGFP cells in tumors. Luciferase was detected intracellularly by specific antibodies and labeled by PerCP-Cy7 antirabbit IgG confirming: the reduced growth of tumor cells in ITPP-treated mice (%) and counts by direct cytometry analysis. Cells were numbered on the basis of intracellular Luciferase detection ( n = 8; * p < 0.05) from dot plots or inset from histogram analysis for quantification of B16F10LucGFP in the tumor

Journal: Journal of Molecular Medicine (Berlin, Germany)

Article Title: Stable tumor vessel normalization with pO 2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment

doi: 10.1007/s00109-013-0992-6

Figure Lengend Snippet: ITPP reduces melanoma tumor growth and improves mice survival. a Effect of ITPP treatment on the kinetics of tumor growth measured by bioluminescence in treated and nontreated animals at days 18 and 24. Endpoint was fixed at 2 cm 3 ( n = 6 animals per group, one representative experiment out of N > 10, ** p < 0.001). b Comparison of tumor size, 23 days after B16F10LucGFP cells injection, showing reduced tumor growth in treated mice. Representative groups of five animals among groups of n = 10 animals. One experiment out of N ≥ 5 separate experiments. Insets illustrate the extreme size ranges (minimal and maximal) that tumor reached in nontreated compared to treated mice. c Mean size of the tumors in treated and non treated animals at day 23 ( n = 10 in each group; number of experiments N > 20, ** p < 0.001). d Magnetic resonance imaging of B16 F10 induced tumor. Morphological pulse sequence ( left ). Strong volume variation of the tumor (untreated/ITPP = 1163 mm 3 /121 mm 3 ) was observed by image analysis after volume reconstruction. One typical example out of n = 10/experimental group. MRA-TOF/saturation recovery pulse sequence ( right ): Necrotic areas appear darker. After ITPP treatment, their size decreased. One typical example out of n = 10/experimental group. e Analysis by flow cytometry of B16LucGFP cells in tumors. Luciferase was detected intracellularly by specific antibodies and labeled by PerCP-Cy7 antirabbit IgG confirming: the reduced growth of tumor cells in ITPP-treated mice (%) and counts by direct cytometry analysis. Cells were numbered on the basis of intracellular Luciferase detection ( n = 8; * p < 0.05) from dot plots or inset from histogram analysis for quantification of B16F10LucGFP in the tumor

Article Snippet: Labeled primary antibodies used were the following: antimouse-CD31-PE (rat Ig-G2a, eBioscience) or CD31-PerCP (rat IgG2a, R&D), -VEGF R1-PE (Rat IgG2b, R&D), -VEGF R2-PE (Rat IgG2a, R&D), -CXCR4-PE (Rat IgG2b, R&D), -CD45-PerCP (rat IgG2b, R&D) or CD45-PE-Cy7 (rat IgG2b, R&D), -CD34-A700 (rat IgG2a, R&D).

Techniques: Injection, Magnetic Resonance Imaging, Sequencing, Flow Cytometry, Luciferase, Labeling, Cytometry

Phenotypic effect of ITPP treatment on tumor metabolism. a RT-PCR analysis revealing: downregulation of hypoxia/oxygen sensing genes and prometastasis genes; upregulation of genes implicated in endothelial cells maturation. Results are percent of non treated samples level ( n = 8 animals, five separate experiments; ** p = 0.001; *** p = 0.0001). b Reduction of the number of CXCR4 + CD34 + CD45 − precursor cells among tumor cells upon ITPP treatment. Quantification by flow cytometry from separate tumor samples ( n = 10/group p < 0.001). c Flow cytometry quantitative analysis showing a dramatic decrease in the number of cells expressing hypoxia-, stress-, and metastasis- related markers in primary tumors (day 22) after ITPP treatments as described in “ ” ( n = 8/group; 5 separate experiments, ** p = 0.001; *** p = 0.0001). d Flow cytometry quantification analysis showing a dramatic decrease in the number of cells expressing markers of high energetic metabolism in primary tumors (day 22) after ITPP treatments as described in “ ” ( n = 8/group; five separate experiments; *** p = 0.0001)

Journal: Journal of Molecular Medicine (Berlin, Germany)

Article Title: Stable tumor vessel normalization with pO 2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment

doi: 10.1007/s00109-013-0992-6

Figure Lengend Snippet: Phenotypic effect of ITPP treatment on tumor metabolism. a RT-PCR analysis revealing: downregulation of hypoxia/oxygen sensing genes and prometastasis genes; upregulation of genes implicated in endothelial cells maturation. Results are percent of non treated samples level ( n = 8 animals, five separate experiments; ** p = 0.001; *** p = 0.0001). b Reduction of the number of CXCR4 + CD34 + CD45 − precursor cells among tumor cells upon ITPP treatment. Quantification by flow cytometry from separate tumor samples ( n = 10/group p < 0.001). c Flow cytometry quantitative analysis showing a dramatic decrease in the number of cells expressing hypoxia-, stress-, and metastasis- related markers in primary tumors (day 22) after ITPP treatments as described in “ ” ( n = 8/group; 5 separate experiments, ** p = 0.001; *** p = 0.0001). d Flow cytometry quantification analysis showing a dramatic decrease in the number of cells expressing markers of high energetic metabolism in primary tumors (day 22) after ITPP treatments as described in “ ” ( n = 8/group; five separate experiments; *** p = 0.0001)

Article Snippet: Labeled primary antibodies used were the following: antimouse-CD31-PE (rat Ig-G2a, eBioscience) or CD31-PerCP (rat IgG2a, R&D), -VEGF R1-PE (Rat IgG2b, R&D), -VEGF R2-PE (Rat IgG2a, R&D), -CXCR4-PE (Rat IgG2b, R&D), -CD45-PerCP (rat IgG2b, R&D) or CD45-PE-Cy7 (rat IgG2b, R&D), -CD34-A700 (rat IgG2a, R&D).

Techniques: Reverse Transcription Polymerase Chain Reaction, Flow Cytometry, Expressing

Effect of ITPP treatment on tumor hypoxia-induced resistance, stem cell selection, and enhancement of chemotherapeutic efficacy. a The P-glycoprotein immunostaining showing a reduced number of multidrug resistance positive tumor cells after ITPP treatment. Frozen sections of primary tumors from experiments described in Fig. were histochemically labeled (day 22, ITPP treatments as described in “ ” ( n = 8/group; five separate experiments). Scale bars = 50 μm. b Quantification by flow cytometry showing the reduction of cells positive for precursor and stem cell-associated markers (CD133, Oct3-4, ABCG-2) after ITPP treatment. CD133 + immunostaining corroborated the reduction visible on frozen section staining of primary tumors as in a . Scale bars = 50 μm. c Lung metastasis is suppressed by chemotherapeutic drugs (Paclitaxel and Cisplatin), when treatment is preceded by ITPP injection. Tumor cells are detected by their Lucifease activity in the lungs of animals from control, ITPP, CisPt plus Paclitaxel and combined treatments ITPP + drugs as described in “ .” Data are reported for day 22 ( n = 10/group; 5 experiments; ***; p = 0.001). d CD31 staining of endothelial cells ( green ) and eosin/hematoxylin staining obtained in primary tumor frozen sections from experiment described in c . Efficient tissue necrosis was obtained when chemotherapeutic treatment is preceded by ITPP injection as described in “ .” Scale bars = 50 μm

Journal: Journal of Molecular Medicine (Berlin, Germany)

Article Title: Stable tumor vessel normalization with pO 2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment

doi: 10.1007/s00109-013-0992-6

Figure Lengend Snippet: Effect of ITPP treatment on tumor hypoxia-induced resistance, stem cell selection, and enhancement of chemotherapeutic efficacy. a The P-glycoprotein immunostaining showing a reduced number of multidrug resistance positive tumor cells after ITPP treatment. Frozen sections of primary tumors from experiments described in Fig. were histochemically labeled (day 22, ITPP treatments as described in “ ” ( n = 8/group; five separate experiments). Scale bars = 50 μm. b Quantification by flow cytometry showing the reduction of cells positive for precursor and stem cell-associated markers (CD133, Oct3-4, ABCG-2) after ITPP treatment. CD133 + immunostaining corroborated the reduction visible on frozen section staining of primary tumors as in a . Scale bars = 50 μm. c Lung metastasis is suppressed by chemotherapeutic drugs (Paclitaxel and Cisplatin), when treatment is preceded by ITPP injection. Tumor cells are detected by their Lucifease activity in the lungs of animals from control, ITPP, CisPt plus Paclitaxel and combined treatments ITPP + drugs as described in “ .” Data are reported for day 22 ( n = 10/group; 5 experiments; ***; p = 0.001). d CD31 staining of endothelial cells ( green ) and eosin/hematoxylin staining obtained in primary tumor frozen sections from experiment described in c . Efficient tissue necrosis was obtained when chemotherapeutic treatment is preceded by ITPP injection as described in “ .” Scale bars = 50 μm

Article Snippet: Labeled primary antibodies used were the following: antimouse-CD31-PE (rat Ig-G2a, eBioscience) or CD31-PerCP (rat IgG2a, R&D), -VEGF R1-PE (Rat IgG2b, R&D), -VEGF R2-PE (Rat IgG2a, R&D), -CXCR4-PE (Rat IgG2b, R&D), -CD45-PerCP (rat IgG2b, R&D) or CD45-PE-Cy7 (rat IgG2b, R&D), -CD34-A700 (rat IgG2a, R&D).

Techniques: Selection, Immunostaining, Labeling, Flow Cytometry, Staining, Injection, Activity Assay